This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Oxygen Biotherapeutics Receives U.S. Army Grant For Studies Of Oxycyte(R), A Novel Traumatic Brain Injury Therapeutic For Combat Casualties

MORRISVILLE, N.C., March 2, 2011 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) today announced it has received a $2.075 million, two-year grant from the U.S. Army to study the Company's proprietary Oxycyte ® PFC emulsion as a therapeutic intervention focused on reducing brain damage in victims of traumatic brain injury (TBI).

Perfluorocarbon (PFC) emulsions, as a therapeutic class, are known to interact with the reticuloendothelial system as part of the clearance mechanism, as well as affect the number of circulating platelets. The preclinical studies supported by this grant will examine the effects of Oxycyte on the immune system, platelet function and distribution, as well as the safety and efficacy of platelet transfusion, which can be necessary for patients with TBI and related polytrauma. Additionally studies will be conducted to further evaluate the pharmacokinetics of PFCs in relevant species to aid in data interpretation.  These studies will help determine the safety profile of Oxycyte PFC emulsion.

"Hemostasis and immunocompetence are critically important in severe TBI patients. The studies supported by this Army grant will augment our data and knowledge of the safety and efficacy of perfluorocarbon emulsions," said Gerald L. Klein, MD, Principal Investigator and Chief Medical Officer of Oxygen Biotherapeutics. "We believe Oxycyte PFC emulsion may have the potential to help reduce the effects of traumatic brain injury rather than merely improve stabilization following the traumatic occurrence."

Added Oxygen Biotherapeutics' Chairman and CEO Chris Stern: "We are proud to work with the U.S. Army to develop new treatments that will benefit our soldiers, as well as civilians. We believe this research grant will give us the important information we need to move Oxycyte down the clinical development path."

TBI Incidence

According to the Department of Defense Personnel and Procurement Statistics, 75% of all U.S. military casualties of Operation Enduring Freedom and Operation Iraqi Freedom are caused by explosive weaponry, resulting in TBIs and blast-induced neurotrauma, which have been called the "signature wounds" of these wars. They estimate that TBI accounts for about 22 percent of all casualties. In a January 2006 report, the Centers for Disease Control (CDC) estimated that 1.4 million U.S. civilians sustain TBI each year. Of them, about 50,000 die, 235,000 are hospitalized and 1.1 million are treated and released from an Emergency Department. An estimated 80,000-90,000 people with TBI experience permanent disability from their injury. These incidence rates have led the CDC to conclude that TBI prevention, improved acute care and rehabilitation to reduce the likelihood of TBI-related disability, and increased access to services for those who do not fully recover must continue to be national priorities.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,943.81 +28.74 0.17%
S&P 500 1,967.57 +2.89 0.15%
NASDAQ 4,415.49 +19.2860 0.44%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs